Skip to main content
Caplight Logo









NeuShen Therapeutics

NeuShen Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://www.neushen.com/

Last Round

Series B

Sep 3, 2026

Total Funding Raised

$20M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

NeuShen Therapeutics is a biotechnology company that develops innovative therapies for neurological and psychiatric disorders using AAV-based gene therapy and small molecule discovery platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryCNS disordersneurodegenerative diseasessmall molecule inhibitorbiotech startupAI drug discoveryclinical-stage biotechpsychiatric conditionstarget identificationin silico drug discoverybiologic therapiespharma licensingcentral nervous systemdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuShen Therapeutics Comparables

Compare NeuShen Therapeutics with similar companies based on industry and business-model similarity.

NeuShen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SciNeuro Pharmaceuticals
88%
Sensorium Therapeutics
82%
Zhongze Therapeutics
79%

NeuShen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 3, 2026
Series A ExtensionJan 28, 2026
Series AApr 18, 2025
Pre SeedSep 29, 2022

Key People

Founding team and executive leadership

Joan Shen

Chief Executive Officer and Founder

Founding Team

NeuShen Therapeutics Investors

Notable investors and investment history

NeuShen Therapeutics investors
InvestorRounds
Shanghai Healthcare CapitalSeries A Extension, Series A
B Capital GroupSeries B
Lapam CapitalSeries A Extension, Series A, Pre Seed
Legend CapitalSeries B
上海国投先导私募基金管理有限公司Series B
TTM CapitalPre Seed, Series A Extension, Series A
MPCSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2026

    $80M round with participation from B Capital Group and Legend Capital.

  • Apr 15, 2026

    Monthly visitors increased 112% MoM.

NeuShen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuShen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuShen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range12
Year Founded2021
Last FundingSep 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?